We are international
Donate
• meetings TEXT SIZE   


Heidelberg Patient & Family Seminar
September 26-28, 2003
Sun, Sep 28, 2003

Where:
Heidelberg, Germany




MEETING OF THE GERMAN-SPEAKING MYELOMA MULTICENTER GROUP (GMMG)
Friday, September 26, 2003
Noon to 5:30 PM

Overview of GMMG-HD3

I. Breitkreutz, Heidelberg
H. Goldschmidt, Heidelberg
Scientific Program GMMG HD3 P.Liebisch, Ulm
F.W. Cremer, Heidelberg
R. Bartl, München
B. Klein, Montpellier
Overview of HOVON H. Lokhorst, Utrecht
Relapse Study TCID A. Glasmacher, Bonn

Schmidt-Wolf, Bonn

Relapse Study TCED Th. Moehler, Heidelberg
Central European Study Group H. Ludwig, Wien
NMAM-2000 EBMT-Study G. Gahrton, Huddinge
TPX in Elderly Patients W. Knauf, Berlin
Revimid-Phase-III-Study TBA
Velcade-Phase-III-Study H. Goldschmidt, Heidelberg
Velcade-Phase-II-Study Kropf, Muenster
Bisphosponates plus IL-2 Kunzmann, Wuerzburg
Ribomustin plus Thal W. Poenisch, Leipzig
Dinner in Vinery
7:00 pm

WORKSHOP "NEW DRUGS AND TRANSPLANTATION IN MULTIPLE MYELOMA
Saturday September 27, 2003
8:00 AM to 3:00 PM
New Drugs in Multiple Myeloma
Chairs: Durie/Bartl/Ho
Thalidomide Goldschmidt, Heidelberg
Revimid Durie, Los Angeles
Velcade TBA
Arsen Ludwig, Wien
New Bisphosphonates Bartl, München

Transplantation of Hematopoietic Cells
Chairs: Gahrton/Lokhorst/Goldschmidt
Autologous SCT after HD-Therapy Goldschmidt, Heidelberg
Autologous SCT after Intermediate Therapy TBA
Allogeneic SCT after HD-Therapy Gahrton, Huddinge
Allogenic SCT after Intermediate Therapy Kröger, Hamburg
Role of T-Cells Lokhorst, Utrecht

SEMINAR OF THE INTERNATIONAL MYELOMA FOUNDATION
Saturday September 27,2003
3:00 PM to 7:00 PM
Opening A.D. Ho
Welcome S. Novis
A. Waldmannn, J. Brosig DLH
Diagnosis and Prognostic Factors B. Durie
Conventional Therapy H. Ludwig
Autologous Transplantation H. Goldschmidt
Allogeneic Transplantation G. Gahrton
Dinner at German Cancer Center
7:00 pm

Sunday September 28, 2003,
9:00 AM to 2:00 PM

Bone Disease

R. Bartl
Anaemia and Supportive Care A. Glasmacher
Psycho-Oncological Support Verres
Alternative Treatment Modalities TBA
New drugs and treatment options B. Durie
The importance of clinical trials Seibert-Grafe
Rehabilitation Stenzinger
Ask the Expert All Speakers
Closing Remarks S. Novis